Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal CancerAlan P. Venook, Charles D. Blanke, Donna Niedzwiecki et al.|JAMA|2017Cited by 891
Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE StudyHoward S. Höchster, Eric Hedrick, Lowell L. Hart et al.|Journal of Clinical Oncology|2008Cited by 623
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)Scott Kopetz, Howard S. Höchster, Katherine A. Guthrie et al.|Journal of Clinical Oncology|2020Cited by 391
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaperArvind Dasari, Scott Kopetz, Van K. Morris et al.|Nature Reviews Clinical Oncology|2020Cited by 365
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyArvind Dasari, Cathy Eng, Tibor Csőszi et al.|The Lancet|2023Cited by 319